and play an important role in cell proliferation. Objectives To describe for the first time in formalin-fixed paraffin-embedded tissue the immunoexpression of TT-Cs in biopsies of normal skin, acquired melanocytic naevi and melanoma, in order to evaluate their role in melanomagenesis and/or tumour progression, their utility as prognostic markers and their possible use in targeted therapies. Methods Tissue samples from normal skin, melanocytic naevi and melanoma were subjected to immunohistochemistry for two TT-Cs (Cav3.1, Cav3.2); markers of proliferation (Ki67), the cell cycle (cyclin D1), hypoxia (Glut1), vascularization (CD31) and autophagy (LC3); BRAF V600E mutation (VE1) and phosphatase and tensin homologue (PTEN). Immunostaining was evaluated by histoscore. In silico analysis was used to assess the prognostic value of TT-C overexpression.
Results TT-C immunoexpression increased gradually from normal skin to common naevi, dysplastic naevi and melanoma samples, but with differences in the distribution of both isoforms. Particularly, Cav3.2 expression was significantly higher in metastatic melanoma than in primary melanoma. Statistical correlation showed a linear interaction between PTEN loss/BRAF V600E/Cav3.1/LC3/ Ki67/cyclin D1/Cav3.2/Glut1. Disease-free survival (DFS) and overall survival correlated inversely with overexpression of Cav3.2. DFS also correlated inversely with overexpression of Cav3.1. Conclusions TT-C immunoexpression on melanocytic neoplasms is consistent with our previous in vitro studies and appears to be related to tumour progression. TT-C upregulation can be considered as a prognostic marker using The Cancer Genome Atlas database. The high expression of Cav3.2 in metastatic melanoma encourages the investigation of the use of TT-C blockers in targeted therapies.
What's already known about this topic?
• Increased expression of voltage-gated calcium channels is a common finding in several neoplasms.
• We have recently reported that T-type Ca 2+ channels (TT-Cs) are upregulated in human melanoma cells and play an important role in cell proliferation, calcium homeostasis and autophagic flux.
What does this study add?
• TT-C immunoexpression increases gradually from normal skin to common naevi, dysplastic naevi and melanoma samples, and expression of the Cav3.2 isoform is augmented in metastatic vs. primary melanoma.
• We demonstrate a significant correlation between Breslow thickness and TT-C expression, and show a positive correlation between the immunoexpression of Cav3.2 and proliferative/hypoxia markers.
• We show a positive association between the expression of the Cav3.1 isoform, the autophagy markers and the presence of the BRAF V600E mutation.
What is the translational message?
• These findings open a new avenue of research regarding the use of T-type blockers in targeted therapies.
Melanoma is the most dangerous form of skin cancer, and its incidence is steadily increasing worldwide. 1, 2 In spite of being the subject of intense laboratory investigations and numerous clinical trials, and the emergence of new and much more effective drugs, the prognosis of metastatic melanoma is still poor.
3 Ca 2+ signalling is suspected to play an important role in the development, viability, survival and motility of cancer cells. 4, 5 It is known that external Ca 2+ is needed to induce cell proliferation and cell-cycle progression in mammalian cells. TT-Cs display unique low-voltage-dependent activation/inactivation and slow deactivation kinetics, and carry depolarizing currents at near-resting membrane potentials. 9 Therefore, these channels may play a direct role in regulating Ca 2+ levels, especially in nonexcitable tissues. 10 Numerous studies have demonstrated that the Ca 2+ influx through VGCCs results in signalling that affects the expression of genes involved in cell proliferation, programmed cell death and apoptosis. 11, 12 It has been described that the expression of Cav3.1 and Cav3.2 isoforms is increased in many cancerous cell types. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Our group has recently reported that TT-Cs are also upregulated in human melanoma and play an important role in melanoma cell proliferation and homeostasis. On the contrary, TTCs are absent or expressed at low levels in cultured human epidermal melanocytes. Moreover, we have demonstrated that pharmacological blockade or gene silencing of TT-Cs induces apoptosis in melanoma cells, which is preceded by endoplasmic reticulum (ER) stress and inhibition of macroautophagy, which is basally activated in this type of tumour cell. 23, 24 Deregulation of autophagy is a common feature in malignancy. Evidence for basal increase of autophagy in melanoma is supported by the immunohistochemical detection of LC3-II [25] [26] [27] [28] [29] and by electron microscopy studies. 30 In particular, recent studies have demonstrated that melanomas harbouring the BRAF V600E mutation display an increased basal autophagic rate. 31 Most of our previous work was done employing melanoma cell lines, cultured human epidermal melanocytes and a few human melanoma biopsies in which the expression of TT-Cs was studied by reverse-transcriptase polymerase chain reaction (RT-PCR). In the present study we have analysed the expression of TT-Cs at the protein level in a series of formalin-fixed paraffin-embedded (FFPE) biopsies of normal skin, acquired common and dysplastic melanocytic naevi, and primary and metastatic melanoma tumours, in order to evaluate their role in melanomagenesis and/or tumour progression, and their utility as prognostic markers. In addition, we have correlated the expression of the distinct TT-C isoforms with proliferative, cell-cycle, autophagy and hypoxia tissue markers, as well as the common mutation V600E in BRAF and mutations in phosphatase and tensin homologue (PTEN).
Materials and methods

Case selection
The series included the following FFPE tissue samples: (i) 21 biopsies of normal skin and 62 biopsies of melanoma tumours (40 primary and 22 metastatic), which were included in three tissue microarrays (Table S1; Table S2 (see Supporting Information).
All tumour samples were obtained from Hospital Arnau de Vilanova, Lleida. The tumours were classified following the most recent World Health Organization criteria. The study was approved by the local ethical committee, and a specific informed consent was used. A tissue arrayer device (Beecher Instruments, Silver Spring, MD, U.S.A.) was used to construct the tissue microarrays. Two selected cylinders (1 mm in diameter) from two different areas were included in each case.
Immunohistochemical study FFPE samples were subjected to immunohistochemistry (IHC) with specific antibodies to two TT-Cs isoforms (Cav3.1, Cav3.2), Ki-67, cyclin D1, Glut1, CD31, LC3, BRAF V600E and PTEN. The optimal IHC conditions and procedures for each antibody are listed in Table 1 . As reliable antibodies were not commercially available, specific novel Cav3.1 and Cav3.2 antibodies were designed by Antibody BCN (Barcelona, Spain) against the following peptides: QRRPTSWLDEQRRHSI for Cav3.1 and FTQDVRHGDRWDPTRP for Cav3.2. Rabbits were immunized with these peptides and raised antibodies were affinity purified. The specificity of antibodies was tested with appropriate positive and negative controls.
IHC staining was graded semiquantitatively by considering the percentage and intensity of the staining. A histological score (Hs) was obtained from each sample and values ranged from 0 (no immunoreactivity) to 300 (maximum immunoreactivity). The score was obtained by applying the following formula, Hs = [1 9 (% light staining)] + [2 9 (% moderate staining)] + [3 9 (% strong staining)]. CD31 and GLUT1 were scored as previously described for membrane markers employing a scale from 0 (null expression) to 3 (strong complete membranous staining). 32 
Statistical analysis
For the statistical analysis, means and SDs from the Hs were calculated to report relative differences in immunoexpression levels between all of the groups included in Table 1 . Levels of immunoexpression of the different groups of samples were compared by Kruskal-Wallis test with Dunn's multiple comparison test. A trend test, using a linear model, was employed to evaluate the progression in the immunoexpression levels in normal skin, acquired common naevi, dysplastic naevi, primary melanoma and metastatic melanoma tissue, using that order. Secondly, the Mann-Whitney test was performed to assess whether immunoexpression was similar according to Breslow thickness (≤ 1 mm vs. > 1 mm). Thirdly, the Kruskal-Wallis test with Dunn's multiple comparison test was performed to study differences in the expression of TT-C isoforms between the different clinicopathological primary melanoma subtypes. Fourthly, Pearson correlation tests were performed to find significant relationships among the biomarkers. Fifthly, the optimal threshold for each biomarker was generated by hazard ratios, and Kaplan-Meier estimates were computed to evaluate both disease-free survival (DFS) and overall survival (OS) by log-rank test to assess significance between survivals curves. We carried out a bioinformatics analysis in order to investigate whether TT-Cs are associated with survival in patients with melanoma using The Cancer Genome Atlas (TCGA) database (http:// www.cbioportal.org) (skin ? cutaneous melanoma; 471 patients). 33, 34 Overexpression of Cav3.1 and Cav3.2 was categorized using an RNA z-score cut-off ≥ 2Á0. DFS and OS were obtained as mentioned previously. All analyses were obtained using R statistical software version 3.01 (R Foundation, Vienna, Austria), and statistical significance was set at 0Á05.
Results
Immunohistochemical expression of T-type Ca 2+ channel isoforms in normal skin, naevi and primary and metastatic melanoma IHC analyses of TT-C isoforms Cav3.1 and Cav3.2 were positive in all FFPE samples and displayed relevant differences regarding the distribution of both isoforms (P < 0Á001 for both). The mean, SD and range of Hs were calculated (Table S3 ; see Supporting Information) and all possible comparisons were evaluated in order to obtain significant differences (Table S4 ; see Supporting Information) by KruskalWallis test with post hoc Dunn's multiple comparison test. On the one hand, Cav3.1 was more highly expressed in all samples of malignant melanoma (metastatic and primary) and dysplastic naevi (Hs mean: 44Á44, 41Á86 and 38Á5, respectively). Significant differences were found in the following pairs: metastatic melanoma vs. normal skin; metastatic melanoma vs. acquired common naevi; primary melanoma vs. acquired common naevi; and dysplastic naevi vs. acquired common naevi (Fig. 1a) .
On the other hand, metastatic melanoma displayed the highest Cav3.2 immunoexpression levels (Hs mean: 220), being significantly different from all other groups (primary melanoma, dysplastic naevi, acquired common naevi and normal skin). Primary melanomas displayed the second highest expression levels of Cav3.2 (Hs mean: 125Á16), a value that was significantly higher than that from normal skin. Despite the fact that no significant differences were observed in Cav3.2 distribution among the naevus subtypes, a significantly higher expression of Cav3.2 in the whole group of naevi vs. normal skin was detected (Fig. 1b) .
A trend of progressively increased expression of TT-Cs from normal skin to metastatic melanoma was significant for both TT-Cs (P < 0Á001) (Table S5 ; see Supporting Information).
Correlation between Breslow thickness and T-type Ca 2+ channel expression in primary melanoma As Breslow thickness is the most important clinicopathological prognostic factor of primary melanoma, we tried to correlate this parameter with TT-C expression. As shown in Table S5 (see Supporting Information) and Figure 2 , our data demonstrate a significant correlation between Breslow thickness and Cav3.1 and Cav3.2 expression (P < 0Á001 for both isoforms). Mean Cav3.1 and Cav3.2 expression levels (Hs mean: 48Á33 and 160Á0, respectively) were higher in the group of primary melanoma tumours with Breslow thickness > 1 mm than in the group of tumours with Breslow thickness ≤ 1 mm (Hs mean: 33Á68 and 83Á42, respectively).
Expression of T-type Ca 2+ channel isoforms between the different clinicopathological primary melanoma subtypes
The presence of Cav3.1 and Cav3.2 isoforms in the main four clinicopathological primary melanoma subtypes [superficial spreading malignant melanoma (SSMM), nodular melanoma (NM), acral lentiginous melanoma (ALM) and lentigo maligna melanoma (LMM)] was also studied (Table S6 ; see Supporting Information). Mean Cav3.1 immunoexpression was low to moderate in all subtypes, and the Hs did not show overall significant differences between them (P = 0Á07) (Fig. 3a) . However, mean Cav3.2 immunoexpression was differentially distributed among primary melanoma subtypes (P < 0Á001) (Table S7 ; see Supporting Information). Cav3.2 immunostaining was strong in NM and ALM (Hs means: 212Á22 and 198Á33, respectively), apparently according to their high Breslow thickness, and low to moderate in SSMMs according to their variable Breslow thickness (Hs mean: 67Á17), with higher expression in very thick SSMMs (Fig. 3b) . However, even the thickest SSMM group (Breslow > 4 mm, Hs mean: 105Á6) did not reach the high Cav3.2 Hs values of the other subtypes. Of note, LMM showed strong Cav3.2 immunoexpression in spite of the very low Breslow thickness of all specimens (Table S2) . Table 1 were subjected to a statistical correlation analysis in all melanoma samples (primary and metastatic). Significant correlations by Pearson test were obtained between some of them, showing a cluster of linear interactions between partial or complete PTEN loss/BRAF V600E/Cav3.1/ LC3/cyclin D1/Ki67/Cav3.2/Glut1. We observed a positive correlation between partial or complete PTEN loss and the presence of the BRAF V600E mutant protein (P < 0Á001). Importantly, this common mutation in melanoma (50-60% of cases) correlated with the expression of Cav3.1 (P < 0Á001). Likewise, the expression of this channel isoform was linked to the expression of LC3, an important protein during the autophagic process. In our samples, the levels of LC3 also correlated with the levels of nuclear cyclin D1 (P = 0Á01). In turn, nuclear cyclin D1 showed a positive correlation with Ki67, a marker of proliferation. Finally, Cav3.2 positively correlated with Ki67 (P = 0Á03) and Glut1 (P = 0Á003), indicating that the expression of this channel isoform is enhanced in hypoxic and proliferative environments (Fig. 4 ). Survival studies: lack of prognostic statistical significance of T-type Ca 2+ channel immunoexpression on disease-free survival and overall survival
Among the 39 patients with a primary tumour, 17 experienced a relapse (44%) and 13 died (33%). The median DFS and OS were 26Á3 months and 51Á6 months, respectively. The median follow-up was 29Á1 months. Statistical univariate analysis looking for clinicopathological parameters and immunohistochemical biomarkers of primary tumours influencing DFS and OS was done. The clinicopathological variables analysed were Breslow thickness and 2010 American Joint Committee on Cancer (AJCC) stages. All biomarkers employed in the present study (Cav3.1, Cav3.2, Ki67, cyclin D1, Glut1, CD31, LC3, BRAF V600E and PTEN) were included as variables. Log-rank-test analysis demonstrated that DFS and OS correlated inversely in a statistically significant way with high AJCC staging (DFS P < 0Á001; OS P = 0Á002), high Breslow thickness (best cut-off 4 mm) (DFS P < 0Á001; OS P < 0Á001), partial or complete PTEN loss (DFS P < 0Á001; OS P < 0Á001) and high Ki67 expression (DFS P = 0Á01; OS P = 0Á02). Low cyclin D1 levels correlated with poor OS (DFS P = 0Á24; OS P = 0Á02). Cav3.1 or Cav3.2 isoform Hs did not show a statistically significant impact on survival (Fig. 5 ).
Survival studies: in silico analysis of the impact of T-type Ca 2+ channel expression at the RNA level on melanoma prognosis
Due to the lack of prognostic statistical significance of TT-C immunoexpression in our series, we studied the impact of TT-C upregulation at the RNA level on DFS and OS in the mentioned database (http://www.cbioportal.org). Samples were followed for up to 360 months. Although shorter times of follow-up were considered ( Fig. S1 ; see Supporting Information), the highest statistical significance was observed at 360 months for both TT-Cs. From a total of 398 cases, only four presented upregulation of Cav3.1 (Fig. 5f ). Nonetheless, a significant reduction was observed for DFS (P = 0Á026), but OS reduction was not significant (P = 0Á16). In contrast, the Cav3.2 RNA levels were upregulated in 17 and 21 cases from a total of 386 and 439 cases for DFS and OS, respectively. The upregulation of Cav3.2 is strongly associated with a poor outcome, represented by significant decreases in DFS and OS (Fig. 5g ) (P = 0Á012 and 0Á007, respectively).
Discussion
Malignant melanoma is one of the most life-threatening cutaneous neoplasms. Therefore, investigation about molecules involved in melanoma pathogenesis and progression, which could be used as prognostic markers and/or targets of new therapeutic strategies, is required. It is currently known that cutaneous melanoma may arise on normal skin or on a previous congenital or acquired melanocytic naevus. 35, 36 However, the Clark model for melanoma progression, in which melanoma develops from benign melanocytic naevus via dysplastic naevus, 37,38 is a useful model to analyse in human specimens the role of potentially relevant molecular targets. Our group has recently reported that TT-Cs are expressed in melanoma cell lines and metastatic melanoma frozen samples. These channels mediate constitutive Ca 2+ influx in melanoma cells and can be efficiently blocked by pharmacological drugs or silenced at the gene level. Both strategies lead to the apoptotic death of the cultured melanoma cells through ER stress and autophagy inhibition. 23, 24 Taking into account our previous findings, we decided to evaluate the immunoexpression of Cav3.1 and Cav3.2 on a series of human samples that contained the spectrum of melanocytes on normal skin, common acquired melanocytic naevi, dysplastic naevi, primary melanoma tumours with diverse Breslow thickness and metastatic melanoma, using made-toorder antibodies. Consistently with our previous work, Cav3.1 and Cav3.2 proteins were expressed at higher levels in melanoma cells than in epidermal melanocytes, especially the expression of Cav3.2 in metastatic tumours. Moreover, TT-C immunoexpression increased gradually from melanocytes of normal skin to common naevi, dysplastic naevi, primary melanoma and metastatic melanoma specimens. This progressive increase sustained our hypothesis about the upregulation of TT-Cs during melanoma progression. This was further supported by the observation that the expression of both isoforms was higher in thick (Breslow > 1 mm) than thin (Breslow ≤ 1 mm) primary tumours.
Regarding the immunostaining of TT-C isoforms among the different clinicopathological primary melanoma subtypes, we did not observe differences in the relationship to Cav3.1. In contrast, the expression of Cav3.2 showed statistical differences depending on the melanoma subtypes. Overall, Cav3.2 immunostaining was stronger in melanomas with high mean Breslow thickness (NM, ALM) and moderate in tumours with variable Breslow thickness (SSMM). Nevertheless, although very thick SSMMs (Breslow > 4 mm) showed higher Cav3.2 immunoexpression than less thick SSMM tumours (Breslow ≤ 4 mm), the differences were not significant. Also, the group of LMMs, which included four in situ (Breslow = 0) and two thin tumours with a mean Breslow of 0Á25 mm, displayed strong Cav3.2 immunostaining. As a matter of fact, the pathogenesis for LMM is quite distinctive and differs from the pathogenesis of SSMM, developing on chronically exposed skin of elderly people, usually with a long-lasting radial growth phase and particular histopathological, molecular and genetic features. 39 As our series included a relatively small number of this LMM subtype (six cases), in comparison with a majority of SSMM tumours (21 cases), but only four SSMMs with Breslow > 4 mm, broader studies will be necessary to confirm this finding. Our previous in vitro findings indicated that the expression of TT-Cs in melanoma cells is modulated under hypoxic conditions and plays a role in melanoma viability and proliferation. 24 Furthermore, their inhibition results in a blockade of 
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Overall survival (%) basal macroautophagy (constitutively activated in melanoma cells). 23 Thus, we decided to check the correlation between the immunoexpression of both TT-C isoforms and proliferation (Ki67), cell-cycle (cyclin D1), hypoxia (Glut1), vascularization (CD31) and autophagy (LC3) biomarkers. In addition, as autophagy has been described to be high in BRAF mutant melanoma, 40 we also tested melanoma samples for the immunoexpression of V600E/BRAF mutated protein (employing the currently commercially available VE1 antibody) 41 and for the frequently concomitant downregulation of the tumor suppressor protein PTEN. 42 In the current work, Cav3.1 immunoexpression nicely correlated with the LC3 autophagy biomarker and with the presence of the BRAF V600E mutation, which, in turn, was associated with PTEN downregulation as described in the previously mentioned melanoma molecular studies. 42 On the other hand, Cav3.2 expression was closely related to the hypoxia marker Glut1 and the proliferation marker Ki67. Transcriptional upregulation of specific TT-C isoforms by hypoxia has been previously reported in proliferating cells, and found to be mediated by hypoxia-inducible factors. [43] [44] [45] Furthermore, the level of Ki67 immunostaining was associated with cyclin D1 expression, which, in turn, correlated with LC3, completing the cluster of linear interactions. In summary, our data support the idea that increased autophagic flux and TT-C expression can be regarded as two mechanisms of cell survival inside a tumour with a high proliferation index in a hypoxic environment. Finally, as we have shown that TT-C expression was related to tumour progression and to adverse prognostic markers of primary tumours such as high Breslow thickness and cell proliferation biomarkers, we checked whether it could also be employed as a prognostic factor. In fact, Pera et al. have recently shown that high levels of Cav3.2 (measured by quantitative RT-PCR) were associated with poor outcome in patients with oestrogen receptor-positive breast cancers, whereas in patients with HER2-positive breast cancers, high Cav3.2 levels were associated with better OS after chemotherapy. 46 Although Cav3.1 or Cav3.2 Hs in primary tumours did not show an impact on the prognosis (OS and DFS) of our patients (n = 39; data not shown), we decided to perform a bioinformatics analysis from a larger number of patients. To this end we searched the TCGA database through cBioPortal 33, 34 and obtained significant, negative associations between the overexpression of Cav3.1 and OS, and between the overexpression of Cav3.2 and OS and DFS. Thus, high RNA levels of TT-Cs are related to bad prognosis, especially for Cav3.2, consistently with a role for these channels in tumour progression/metastasis. Otherwise, classical clinicopathological and immunohistochemical prognostic variables such as high Breslow thickness, advanced AJCC stage and high Ki67 expression were associated with short DFS and poor OS in our sample series, as expected. PTEN downregulation was also identified as a negative predictor for DFS and OS, as previously shown. 47 Intriguingly, high cyclin D1 values were associated with better OS, differing from some other studies on melanoma 48, 49 and other neoplasms. 50 However, others claimed that cyclin D1 immunoexpression levels lacked prognostic value in melanoma 51 or even correlated with longer OS in patients with breast cancer. 52 Although nuclear expression of cyclin D1 is useful to evaluate cell proliferation, 53,54 these discrepancies could be explained by recent reports of new functions of cyclin D1 that go beyond its classical role in the cell cycle and tumorigenesis. 55 In summary, here we describe for the first time the immunoexpression of TT-C isoforms in a series of FFPE tissue samples of human acquired melanocytic naevi and melanoma. We have found that the expression of Cav3.1 and Cav3.2 in normal skin and benign and malignant melanocytic neoplasms is in line with our previous in vitro studies in which TT-C transcript levels were studied, 23 ,24 and appears to be related to tumour progression. Furthermore, the high expression of Cav3.2 in metastatic vs. primary melanoma and its association with proliferative and hypoxia markers, on one hand, and the positive correlation between Cav3.1, autophagy markers and BRAF V600E mutation on the other, opens a new avenue of research regarding the use of TT-C blockers in targeted therapies.
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